Navigation Links
Anavex comments on failure of Pfizer and Medivation's Alzheimer's investigational drug Dimebon during Phase 3 clinical trials
Date:3/3/2010

GENEVA, SWITZERLAND, March 3 /PRNewswire-FirstCall/ - Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today issued a statement following today's announcement from Pfizer and Medivation (MDVN) that their investigational Alzheimer's drug Dimebon did not meet either its co-primary or secondary endpoints compared to placebo during pivotal Phase 3 clinical trials.

"While this is disappointing for the Alzheimer's community, there have been many doubts expressed about Dimebon. These doubts have been documented by leading scientists, including ex-National Institutes of Health (NIH) staffers. This failure of Dimebon, which was hypothesized to act as a mitochondrial pore blocker, on top of the repeated failures of every drug studied for removing beta amyloid from the brain as a way to manage Alzheimer's disease, suggests that novel mechanisms of action that attempt to modify the disease itself, rather than treat symptoms, are necessary," said Cameron Durrant, MD, MBA, Executive Chairman of the ANAVEX Board of Directors.

ANAVEX is preparing to enter Phase 1 clinical trials with ANAVEX 2-73, its lead compound for the treatment of Alzheimer's disease, later this year.

ANAVEX 2-73 is a first of a new class of oral, disease-modifying drugs for the treatment of Alzheimer's disease, which employ an approach that targets neither amyloid, nor tau, nor mitochondrial pore blockade.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp. (www.anavex.com) is a publicly traded biopharmaceutical company engaged in the discovery and development of novel drug candidates for the treatment of cancer and neurological diseases such as Alzheimer's, epilepsy, depression and pain. The company's proprietary SIGMACEPTOR(TM) Discovery Platform involves the rational design of drug compounds that fulfill specific criteria and are targeted to specific receptors involved in the modulation of multiple cellular biochemical signaling pathways.

ANAVEX's SIGMACEPTOR(TM)-N program involves the development of novel and original drug candidates that target neurological and neurodegenerative diseases (Alzheimer's disease, epilepsy, depression, pain). The company's lead drug candidates exhibit high, non-exclusive affinity for sigma receptors, which have been extensively documented as potentially valuable drug targets and have demonstrated evidence for anti-amnesic and neuroprotective properties. The company is developing non-amyloid focused approaches to disease modification in Alzheimer's disease. ANAVEX 1-41 and ANAVEX 2-73 modulate sigma receptors, a unique class of receptor molecules, to guard against oxidative stress and work through alternative mitochondrial pathways via ion channel signalling. So far the compounds have performed extremely well in well-recognized animal models of Alzheimer's disease, underscoring the promise of the company's new alternative approach to the disease.

ANAVEX's SIGMACEPTOR(TM)-C program involves the development of novel and original drug candidates targeting cancer. The company's lead drug candidates exhibit high, non-exclusive affinity for sigma receptors with strong evidence for selective pro-apoptotic, anti-metastatic and low toxicity properties in various types of solid cancers. ANAVEX 7-1037 has already demonstrated its ability to significantly delay the growth of cancerous tumors in patient-derived xenografts during advanced pre-clinical studies.

Forward-Looking Statements

Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Forward-looking statements in this press release include that our drug compounds show promise to combat certain diseases. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in drug discovery and development, which include, without limitation, the potential failure of development candidates to advance through preclinical studies or demonstrate safety and efficacy in clinical testing and the ability to file an IND or commence clinical studies. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.

SOURCE Anavex Life Sciences Corp.

Back to top
'/>"/>
SOURCE Anavex Life Sciences Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
2. Anavex 7-1037 reduces rate of cancer tumor growth 69% in pre-clinical studies, compared to currently marketed drug Dacarbazine showing no measurable activity
3. Anavex strengthens Board of Directors
4. Anavex advances drug candidate for treatment of Alzheimers disease
5. American Medical Informatics Association (AMIA) Submits Comments to Hit Policy Committee About Meaningful Use and Electronic Health Record Certification
6. Amylin Comments on RiskMetrics Report
7. The Society of Forensic Toxicologists Comments on the National Academy of Sciences Report on Strengthening Forensic Science in the United States
8. American Oriental Bioengineering Comments on Recent Property Purchase
9. Boston Scientific Provides Comments Reinforcing Strength of Its Balance Sheet
10. Dietitian Mary Lee Chin Comments on Proven Value and Safety of Food Biotechnology in New Online Video
11. KV Pharmaceutical Company Comments on Legal Development in Its Branded Pharmaceutical Business
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/1/2017)... 1, 2017  Cryoport (NASDAQ: CYRX, CYRXW) ("Cryoport" or ... to the life sciences industry, today announced the launch ... reproductive health market. CryoStork SM Next Flight Out ... for reproductive health patients, providing express transportation across ... for reproductive health commodities such as sperm, eggs, embryos ...
(Date:3/1/2017)... SHANGHAI , March 1, 2017 ... Cork based Biotechnology Company and HD ... discovery Contract Research Organization (CRO), announced today that ... and provide new assay technologies for preclinical drug ... access to Luxcel,s state-of-the-art assays and technologies for ...
(Date:3/1/2017)... WA (PRWEB) , ... March 01, 2017 , ... ... research into the physiology of aging into clinical applications, announces the formation of ... proprietary oral-transmucosal dosage form of resveratrol, the drug which has been discussed in ...
(Date:2/28/2017)... ... , ... Surface Plasmon Resonance (SPR) is a widely-used, label-free technique to characterize ... changes in the dielectric properties of the medium close to a metal surface. ... to 300 nm above the metal surface (Au) and thus by the material absorbed ...
Breaking Biology Technology:
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist ... as its new chief executive officer (CEO). Freischlag joins ... John D. McConnell , M.D., who last year ... at the Medical Center, after leading it since 2008. ... full scope of Wake Forest Baptist,s academic health system, ...
(Date:2/10/2017)... Research and Markets has announced ... - Scientific and Commercial Aspects" to their offering. ... Biomarkers ... with therapy for selection of treatment as well for monitoring ... of disease in modern medicine. Biochip/microarray technologies and next generation ...
(Date:2/8/2017)... BEDFORD, Mass., Feb. 7, 2017  Aware, Inc. (NASDAQ: ... services, today reported financial results for its quarter and year ... fourth quarter of 2016 was $3.9 million compared to $6.9 ... the fourth quarter of 2016 was $0.6 million compared to ... in the fourth quarter of 2016 was $0.5 million, or ...
Breaking Biology News(10 mins):